Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
RESEARCH TOOLSreports
Holding BTAI?
Track your performance easily
BTAI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.50 - $4.17
Previous Close$0.57
Volume909.06K
Average Volume (3M)486.01K
Market Cap
$21.91M
Enterprise Value$88.61M
Total Cash (Recent Filing)$40.39M
Total Debt (Recent Filing)$104.60M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Mar 06, 2025EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding42,748,364
10 Day Avg. Volume532,002
30 Day Avg. Volume486,015
Standard Deviation0.35
R-Squared0.00184
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-0.29
Price to Sales (P/S)11.32
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue38.93
Enterprise Value/Gross Profit738.39
Enterprise Value/Ebitda-1.59
Forecast
1Y Price Target
$4.33Price Target Upside744.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bioxcel Therapeutics News
PremiumCompany Announcements
Bioxcel Therapeutics Restructures Credit and Strengthens Leadership
PremiumCompany Announcements
BioXcel Therapeutics Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation of the Phase 3 SERENITY At-Home study for Igalmi is seen as a positive development, potentially driving increased revenue.
Market OpportunityBTAI's most recent market research suggests that the schizophrenia/bipolar disorder at-home market opportunity may be larger than the 23 million episodes it initially had estimated.
Strategic FocusThe strategic decision to focus resources on clinical development and reduce commercial spending is a sound one.
Bears Say
Financial PerformanceThe company's financial situation is a major concern due to limited cash and the need to raise additional funds to meet debt covenants.
Sales And RevenueBTAI reported much lower than expected Igalmi sales, which missed consensus estimates significantly.
Strategic ChallengesGiven virtual elimination of BTAI's commercial efforts for Igalmi, it's unclear what the near-term impact will be to the current trajectory of Igalmi sales.
---
Ownership Overview
48.95% Insiders
4.40% Mutual Funds
0.47% Other Institutional Investors
43.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BTAI FAQ
What was Bioxcel Therapeutics Inc’s price range in the past 12 months?
Bioxcel Therapeutics Inc lowest stock price was $0.50 and its highest was $4.17 in the past 12 months.
What is Bioxcel Therapeutics Inc’s market cap?
Currently, no data Available
When is Bioxcel Therapeutics Inc’s upcoming earnings report date?
Bioxcel Therapeutics Inc’s upcoming earnings report date is Mar 06, 2025 which is in 103 days.
How were Bioxcel Therapeutics Inc’s earnings last quarter?
Bioxcel Therapeutics Inc released its earnings results on Nov 14, 2024. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.506 by $0.186.
Is Bioxcel Therapeutics Inc overvalued?
According to Wall Street analysts Bioxcel Therapeutics Inc’s price is currently Undervalued.
Does Bioxcel Therapeutics Inc pay dividends?
Bioxcel Therapeutics Inc does not currently pay dividends.
What is Bioxcel Therapeutics Inc’s EPS estimate?
Bioxcel Therapeutics Inc’s EPS estimate is -$0.36.
How many shares outstanding does Bioxcel Therapeutics Inc have?
Bioxcel Therapeutics Inc has 42,748,363 shares outstanding.
What happened to Bioxcel Therapeutics Inc’s price movement after its last earnings report?
Bioxcel Therapeutics Inc reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.506. Following the earnings report the stock price went down -16.129%.
Which hedge fund is a major shareholder of Bioxcel Therapeutics Inc?
Among the largest hedge funds holding Bioxcel Therapeutics Inc’s share is Driehaus Capital Management LLC. It holds Bioxcel Therapeutics Inc’s shares valued at N/A.
---
Bioxcel Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.33 (744.88% Upside)
$4.33 (744.88% Upside)
Blogger Sentiment
Bullish
BTAI Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 22.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-51.33%
Trailing 12-Months
Company Description
Bioxcel Therapeutics Inc
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
---
BTAI Earnings Call
Q3 2024
0:00 / 0:00
---
BTAI Stock 12 Month Forecast
Average Price Target
$4.33
▲(744.88% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Aldeyra Therapeutics
―
Avenue Therapeutics
―
Cyclerion Therapeutics
―
Best Analysts Covering BTAI
1 Year
1 Year Success Rate
12/39 ratings generated profit
1 Year Average Return
+39.46%
reiterated a buy rating 3 months ago
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of +39.46% per trade.
---